A new study has shown lobular breast cancer lawyer and hormone replacement therapy attorney Casey Flynn that hormone replacement therapy places users at a higher risk of lobular breast cancer. Lobular breast cancer is a rare cancer that has been associated with hormone therapy. If you have been diagnosed with lobular breast cancer, you should immediately contact a lobular breast cancer lawyer or hormone replacement therapy attorney to discuss your legal rights and the potential for compensation for your lobular breast cancer caused by hormone replacement therapy.
Researchers reported that hormone replacement therapy (HRT) significantly increases the risk of an particular type of breast cancer. The study found those who took combined estrogen/progestin hormone replacement therapy for three years or more had four times the risk of lobular breast cancer. The study, published in the January issue of Cancer Epidemiology, Biomarkers and Prevention, is one of dozens of studies looking to clarify the dangers of taking HRT to treat menopause symptoms. “Previous research indicated that five or more years of combined hormone-therapy use was necessary to increase overall breast-cancer risk,” Dr. Christopher Li of the Fred Hutchinson Cancer Research Center, who led the study, said. “Our study, the first specifically designed to evaluate the relationship between combined HRT and lobular breast cancers, suggests that a significantly shorter length of exposure to such hormones may confer an increased risk,” he added.
According to the American Cancer Society, lobular breast cancer accounts for about 10 percent of all invasive breast cancers, the cancers that most threaten to spread to other parts of the body. The cancer can be treated with hormone-based therapies such as tamoxifen, but the tumors are more difficult to detect by mammograms, so that the cancer is generally diagnosed in more advanced stages.
